Award
Definitive Contract #75F40126C00106
Contract Awarded to University of Liverpool for Genome Sequencing of BDBV
Buyer
Food and Drug Administration
Award Amount
$349,994.70
Ceiling
$349,994.70
Awarded
August 21, 2026
Period of Performance
Aug 21, 2026 – Feb 20, 2027
Identifier
75F40126C00106
NAICS
541714
This award represents a definitive contract granted to the University of Liverpool, a leading academic institution specializing in biomedical research. The contract focuses on sequencing and characterizing the genome of the Bundibugyo ebolavirus (BDBV) during a current outbreak, aiming specifically to sequence and analyze viral genomes from up to 1,000 patients. This contract is significant for public health agencies, as it supports efforts to better understand the virus's genetics and informs outbreak response strategies. The scope includes comprehensive genome sequencing and analysis, delivering critical data to aid in disease surveillance and control. The award was competitively obtained based on scientific merit, reflecting the university's expertise in genomic research. The multi-year contract covers a period from late 2026 to early 2027, ensuring timely completion of deliverables aligned with outbreak management needs. The work will be performed in the United Kingdom, and while no subcontractors or contract vehicles were specified, the contract's focused scope underscores its importance in infectious disease genomics.
Description
EO 14398 - THIS PROJECT SHALL SEQUENCE AND CHARACTERIZE THE GENOME OF BDBV IN THE CURRENT OUTBREAK, WITH A SPECIFIC TARGET TO SEQUENCE AND ANALYZE THE BDBV GENOME FROM AS MANY AS 1,000 PATIENTS